By Scientia Professor Vlado Perkovic

Journal articles

Fletcher RA; Herrington WG; Agarwal R; Mayne KJ; Arnott C; Jardine MJ; Mahaffey KW; Perkovic V; Staplin N; Wheeler DC; Chertow GM; Heerspink HJL; Neuen BL, 2024, 'Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Cause-Specific Cardiovascular Death in Patients with CKD A Meta-Analysis of CKD Progression Trials', Clinical Journal of the American Society of Nephrology, 19, pp. 1180 - 1182, http://dx.doi.org/10.2215/CJN.0000000000000470

Cardoza K; Kang A; Smyth B; Yi TW; Pollock C; Agarwal R; Bakris G; Charytan DM; de Zeeuw D; Wheeler DC; Zhang H; Cannon CP; Perkovic V; Arnott C; Levin A; Mahaffey KW, 2024, 'Geographic and racial variability in kidney, cardiovascular and safety outcomes with canagliflozin: A secondary analysis of the CREDENCE randomized trial', Diabetes Obesity and Metabolism, 26, pp. 3530 - 3540, http://dx.doi.org/10.1111/dom.15685

Junek ML; Merkel PA; Vilayur E; Wald R; Khalidi N; Jayne D; Walsh M; Paizis K; Reidlinger D; Morrish A; Badve SV; Pascoe E; Paul-Brent PA; Robison L; Valks A; Walters G; Jardine M; Milton C; Ibraham A; Siva B; Desmond M; Perkovic V; Kurtkoti J; Cass A; Summers S; Brown F; Ryan J; Kerr P; Noble E; Luxton G; Mudge DW; Hawley C; Johnson DW; Peh CA; Faull RJ; Ranganathan D; Jeffs L; Nicholls K; Hughes P; Cooper B; Boudville N; Ford S; Langham R; Blockmans D; Henckaerts L; Sprangers B; Suri R; Brachemi S; Clark W; Garg A; Carette S; Pagnoux C; Reich H; Barth D; Walsh M; Cox G; Mazzetti A; Robins D; Perl J; Pavenski K; Dacouris N; Levin A; Copland M; Fairhead T; Pannu N; Qarni MU; Habib S; Girard L; Manns B; Tesar V; Hruskova Z; Chocova Z; Povlsen J; Gregersen J; Ivarsen P; Birn H; Krarup E; Pedersen EB; Thomsen I; Bech JN; Szpirt W; Egfjord M; Mesbah R; Bataille P; Rey I; Gombert B; Chantrel F; Vanhille P; Quémeneur T; Carron PL; Zaoui P; de Moreuil C; Gosselin M; Delluc A; Hanrotel-Saliou C; Le Jeune M; Ficheux M, 2024, 'Risk of Relapse of Antineutrophil Cytoplasmic Antibody–Associated Vasculitis in a Randomized Controlled Trial of Plasma Exchange and Glucocorticoids', Arthritis and Rheumatology, 76, pp. 1431 - 1438, http://dx.doi.org/10.1002/art.42843

Apperloo EM; Neuen BL; Fletcher RA; Jongs N; Anker SD; Bhatt DL; Butler J; Cherney DZI; Herrington WG; Inzucchi SE; Jardine MJ; Liu CC; Mahaffey KW; McGuire DK; McMurray JJV; Neal B; Packer M; Perkovic V; Sabatine MS; Solomon SD; Staplin N; Szarek M; Vaduganathan M; Wanner C; Wheeler DC; Wiviott SD; Zannad F; Heerspink HJL, 2024, 'Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials', Lancet Diabetes and Endocrinology, 12, pp. 545 - 557, http://dx.doi.org/10.1016/S2213-8587(24)00155-4

Tangri N; Ferguson TW; Bamforth RJ; Leon SJ; Arnott C; Mahaffey KW; Kotwal S; Heerspink HJL; Perkovic V; Fletcher RA; Neuen BL, 2024, 'Machine learning for prediction of chronic kidney disease progression: Validation of the Klinrisk model in the CANVAS Program and CREDENCE trial', Diabetes Obesity and Metabolism, 26, pp. 3371 - 3380, http://dx.doi.org/10.1111/dom.15678

Neuen BL; Claggett BL; Perkovic V; Jardine M; Heerspink HJL; Mahaffey KW; McMurray JJV; Solomon SD; Vaduganathan M, 2024, 'Timing of Cardio-Kidney Protection With SGLT2 Inhibitors: Insights From 4 Large-Scale Placebo-Controlled Outcome Trials', Circulation, 150, pp. 343 - 345, http://dx.doi.org/10.1161/CIRCULATIONAHA.124.069382

Perkovic V; Tuttle KR; Rossing P; Mahaffey KW; Mann JFE; Bakris G; Baeres FMM; Idorn T; Bosch-Traberg H; Lausvig NL; Pratley R, 2024, 'Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes', New England Journal of Medicine, 391, pp. 109 - 121, http://dx.doi.org/10.1056/NEJMoa2403347

Kim D; Lv J; Hladunewich M; Jha V; Hooi LS; Monaghan H; Shan S; Reich HN; Barbour S; Billot L; Zhang H; Perkovic V; Wong MG; Levin A; Cattran D; Johnson DW; Wheeler D; Flöge J; Woodward M; Jardine M; Zhao MH; Agarwal R; Glassock R; Chan TM; Wu Y; Liu Z, 2024, 'The Efficacy and Safety of Reduced-Dose Oral Methylprednisolone in High-Risk Immunoglobulin A Nephropathy', Kidney International Reports, 9, pp. 2168 - 2179, http://dx.doi.org/10.1016/j.ekir.2024.03.032

Patel SM; Kang YM; Im KA; Neuen BL; Anker SD; Bhatt DL; Butler J; Cherney DZI; Claggett BL; Fletcher RA; Herrington WG; Inzucchi SE; Jardine MJ; Mahaffey KW; McGuire DK; McMurray JJV; Neal B; Packer M; Perkovic V; Solomon SD; Staplin N; Vaduganathan M; Wanner C; Wheeler DC; Zannad F; Zhao Y; Heerspink HJL; Sabatine MS; Wiviott SD, 2024, 'Sodium-Glucose Cotransporter-2 Inhibitors and Major Adverse Cardiovascular Outcomes: A SMART-C Collaborative Meta-Analysis', Circulation, 149, pp. 1789 - 1801, http://dx.doi.org/10.1161/CIRCULATIONAHA.124.069568

Fussner LA; Flores-Suárez LF; Cartin-Ceba R; Specks U; Cox PG; Jayne DRW; Merkel PA; Walsh M; Paizis K; Walters G; Jardine M; Milton C; Ibraham A; Siva B; Desmond M; Perkovic V; Kurtkoti J; Vilayur E; Cass A; Summers S; Brown F; Ryan J; Kerr P; Noble E; Luxton G; Mudge DW; Hawley C; Johnson DW; Peh CA; Faull RJ; Ranganathan D; Jeffs L; Nicholls K; Hughes P; Cooper B; Boudville N; Ford S; Langham R; Reidlinger D; Morrish A; Badve SV; Pascoe E; Paul-Brent PA; Robison L; Valks A; Blockmans D; Henckaerts L; Sprangers B; Suri R; Brachemi S; Clark W; Garg A; Carette S; Pagnoux C; Reich H; Barth D; Khalidi N; Cox G; Mazzetti A; Robins D; Wald R; Perl J; Pavenski K; Dacouris N; Levin A; Copland M; Fairhead T; Pannu N; Qarni MU; Habib S; Girard L; Manns B; Tesar V; Hruskova Z; Chocova Z; Povlsen J; Gregersen J; Ivarsen P; Birn H; Krarup E; Pedersen EB; Thomsen I; Bech JN; Szpirt W; Egfjord M; Mesbah R; Bataille P; Rey I; Chantrel F; Vanhille P; Quémeneur T; Carron PL; Zaoui P; de Moreuil C; Gosselin M; Delluc A; Hanrotel-Saliou C; Le Jeune M; Ficheux M; Aniort J, 2024, 'Alveolar Hemorrhage in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Results of an International Randomized Controlled Trial (PEXIVAS)', American Journal of Respiratory and Critical Care Medicine, 209, pp. 1141 - 1151, http://dx.doi.org/10.1164/rccm.202308-1426OC

Heerspink HJL; Stack AG; Terkeltaub R; Jongs N; Inker LA; Bjursell M; Maklad N; Perl S; Eklund O; Rikte T; Sjöström CD; Perkovic V; Chmelickova H; Lukac M; Bucek P; Drasnar T; Dussol B; Guerrot D; Legrand E; Boffa JJ; Halimi JM; Zaoui P; Letoha A; Hajdu C; Pall D; Peterfai E; Csécsei G; Bezzegh K; Deak L; Konyves L; Zsom M; Danos P; Vangel S; Vasas S; Oroszlan T; Zilahi Z; Leiba A; Grossman A; Leibowitz A; Itzhak B; Daoud D; Farber E; Adawi F; Nakhoul FM; Chernin G; Kenis I; Wainstein J; Zeller L; Elias M; Atar S; Frajewicki V; Yagil Y; Armaly ZA; Esposito C; Viazzi F; Gambaro G; Piatti P; Bonadonna RC; Arias Delgadillo CR; Flores FJ; Aguilera Real ME; Fajardo-Campos P; Violante Ortiz RM; Luna Ceballos RI; Duran-Barragan S; Zytkiewicz-Jaruga D; Krzyzagorska E; Skokowska E; Klodawska K; Mordaka R; Mazur S; Stasinska T; Sulowicz W; Constantin C; Negru D; Paveliu FS; Negrisanu GD; Szilagyi I; Busegeanu MMG; Pena MC; Avram RI; Ardelean SL; Ilavska A; Dzupina A; Oroszova A; Kolesarova E; Obetkova I; Smatanova I; Babikova J; Fulop P; Haffner R; Rayner BL; Kruger DS; Urbach DV; Mitha E; Vally Mahomed Latiff GH; Makan H; Du Plessis H; Jurgens JC; Reddy J, 2024, 'Combination Treatment with Verinurad and Allopurinol in CKD: A Randomized Placebo and Active Controlled Trial', Journal of the American Society of Nephrology, 35, pp. 594 - 606, http://dx.doi.org/10.1681/ASN.0000000000000326

Cunningham JW; Claggett BL; Lopes RD; McMurray JJV; Perkovic V; Carroll K; Hiemstra T; Khavandi K; Lukas MA; Ranganathan P; Shannon J; Van Adelsberg J; Singh AK; Solomon SD, 2024, 'Daprodustat and Heart Failure in CKD', Journal of the American Society of Nephrology, 35, pp. 607 - 617, http://dx.doi.org/10.1681/ASN.0000000000000321

Trachtman H; Radhakrishnan J; Rheault MN; Alpers CE; Barratt J; Heerspink HJL; Noronha IL; Perkovic V; Rovin B; Trimarchi H; Wong MG; Mercer A; Inrig J; Rote W; Murphy E; Bedard PW; Roth S; Bieler S; Komers R, 2024, 'Focal Segmental Glomerulosclerosis Patient Baseline Characteristics in the Sparsentan Phase 3 DUPLEX Study', Kidney International Reports, 9, pp. 1020 - 1030, http://dx.doi.org/10.1016/j.ekir.2024.01.032

Rossing P; Baeres FMM; Bakris G; Bosch-Traberg H; Gislum M; Gough SCL; Idorn T; Lawson J; Mahaffey KW; Mann JFE; Mersebach H; Perkovic V; Tuttle K; Pratley R, 2024, 'The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease', NEPHROLOGY DIALYSIS TRANSPLANTATION, 39, pp. 724 - 724, http://dx.doi.org/10.1093/ndt/gfad252

Kim D; Perkovic V; Kotwal S, 2024, 'Barriers to Care: New Medications and CKD', Kidney International Reports, 9, pp. 504 - 507, http://dx.doi.org/10.1016/j.ekir.2023.12.012

Tobe SW; Mavrakanas TA; Bajaj HS; Levin A; Tangri N; Slee A; Neuen BL; Perkovic V; Mahaffey KW; Rapattoni W; Ang FG, 2024, 'Impact of Canagliflozin on Kidney and Cardiovascular Outcomes by Type 2 Diabetes Duration: A Pooled Analysis of the CANVAS Program and CREDENCE Trials', Diabetes Care, 47, pp. 501 - 507, http://dx.doi.org/10.2337/dc23-1450

Ha JT; Freedman SB; Kelly DM; Neuen BL; Perkovic V; Jun M; Badve SV, 2024, 'Kidney Function, Albuminuria, and Risk of Incident Atrial Fibrillation: A Systematic Review and Meta-Analysis', American Journal of Kidney Diseases, 83, pp. 350 - 359.e1, http://dx.doi.org/10.1053/j.ajkd.2023.07.023

Cheung CK; Barratt J; Carroll K; Lafayette RA; Liew A; Suzuki Y; Tesař V; Trimarchi H; Wong MG; Zhang H; Perkovic V; Rizk DV, 2024, 'Targeting APRIL in the Treatment of IgA Nephropathy', Clinical Journal of the American Society of Nephrology, 19, pp. 394 - 398, http://dx.doi.org/10.2215/CJN.0000000000000338

Tangri N; Mathur VS; Bushinsky DA; Klaerner G; Li E; Parsell D; Stasiv Y; Walker M; Wesson DE; Wheeler DC; Perkovic V; Inker LA, 2024, 'VALOR-CKD: A Multicenter, Randomized, Double-Blind Placebo-Controlled Trial Evaluating Veverimer in Slowing Progression of CKD in Patients with Metabolic Acidosis', Journal of the American Society of Nephrology, 35, pp. 311 - 320, http://dx.doi.org/10.1681/ASN.0000000000000292

Marx N; Kolkailah AA; Rosenstock J; Johansen OE; Cooper ME; Alexander JH; Toto RD; Wanner C; Espeland MA; Mattheus M; Schnaidt S; Perkovic V; Gollop ND; McGuire DK, 2024, 'Hypoglycemia and Cardiovascular Outcomes in the CARMELINA and CAROLINA Trials of Linagliptin A Secondary Analysis of Randomized Clinical Trials', JAMA Cardiology, 9, pp. 134 - 143, http://dx.doi.org/10.1001/jamacardio.2023.4602

Neuen BL; Heerspink HJL; Vart P; Claggett BL; Fletcher RA; Arnott C; de Oliveira Costa J; Falster MO; Pearson SA; Mahaffey KW; Neal B; Agarwal R; Bakris G; Perkovic V; Solomon SD; Vaduganathan M, 2024, 'Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria', Circulation, 149, pp. 450 - 462, http://dx.doi.org/10.1161/CIRCULATIONAHA.123.067584

Sharma A; Razaghizad A; Joury A; Levin A; Bajaj HS; Mancini GBJ; Wong NC; Slee A; Ang FG; Rapattoni W; Neuen BL; Arnott C; Perkovic V; Mahaffey KW, 2024, 'Primary and Secondary Cardiovascular and Kidney Prevention With Canagliflozin: Insights From the CANVAS Program and CREDENCE Trial', Journal of the American Heart Association, 13, http://dx.doi.org/10.1161/JAHA.123.031586

Neuen BL; Jun M; Wick J; Kotwal S; Badve SV; Jardine MJ; Gallagher M; Chalmers J; Nallaiah K; Perkovic V; Peiris D; Rodgers A; Woodward M; Ronksley PE, 2024, 'Estimating the population-level impacts of improved uptake of SGLT2 inhibitors in patients with chronic kidney disease: a cross-sectional observational study using routinely collected Australian primary care data', Lancet Regional Health Western Pacific, 43, http://dx.doi.org/10.1016/j.lanwpc.2023.100988

Jun M; Wick J; Neuen BL; Kotwal S; Badve SV; Woodward M; Chalmers J; Peiris D; Rodgers A; Nallaiah K; Jardine MJ; Perkovic V; Gallagher M; Ronksley PE, 2024, 'The Prevalence of CKD in Australian Primary Care: Analysis of a National General Practice Dataset', Kidney International Reports, 9, pp. 312 - 322, http://dx.doi.org/10.1016/j.ekir.2023.11.022

Sharma A; Marques P; Neuen BL; Fletcher RA; Slee A; Rapattoni W; Ang FG; Arnott C; Levin A; Verma S; Perkovic V; Mahaffey KW, 2024, 'Timing of statistical benefit of canagliflozin in patients with type 2 diabetes for cardiovascular and heart failure outcomes: Insights from the CANVAS Program and CREDENCE trial', Diabetes Obesity and Metabolism, 26, pp. 758 - 762, http://dx.doi.org/10.1111/dom.15340

Kotwal S; Perkovic E; Perkovic V, 2024, 'Combination therapy with kidney protective therapies: Optimizing the benefits?', Current Opinion in Nephrology and Hypertension, 33, pp. 136 - 143, http://dx.doi.org/10.1097/MNH.0000000000000929

Pergola PE; Davidson M; Jensen C; Mohseni Zonoozi AA; Raj DS; Andreas Schytz P; Tuttle KR; Perkovic V, 2024, 'Effect of Ziltivekimab on Determinants of Hemoglobin in Patients with CKD Stage 3-5: An Analysis of a Randomized Trial (RESCUE)', Journal of the American Society of Nephrology, 35, pp. 74 - 84, http://dx.doi.org/10.1681/ASN.0000000000000245

Zhang H; Rizk DV; Perkovic V; Maes B; Kashihara N; Rovin B; Trimarchi H; Sprangers B; Meier M; Kollins D; Papachristofi O; Milojevic J; Junge G; Nidamarthy PK; Charney A; Barratt J, 2024, 'Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy', Kidney International, 105, pp. 189 - 199, http://dx.doi.org/10.1016/j.kint.2023.09.027

Ketema DB; Wallace H; Neuen BL; Kotwal SS; Ronksley PE; Badve S; Perkovic V; Gallagher MP; Joshi R; Jun M, 2024, 'Assessing the Quality of Care for People with CKD: A Systematic Review and Meta-Analysis', Journal of the American Society of Nephrology, 35, http://dx.doi.org/10.1681/asn.2024bzcfkb63

Siriwardana A; Jardine M; Perkovic V; Jun M; Kotwal SS; Arnott CG; Neuen BL, 2024, 'Cardiovascular, Kidney, and Safety Outcomes with Canagliflozin in Older Adults: A Pooled Secondary Analysis of the CANVAS Program and CREDENCE Trial', Journal of the American Society of Nephrology, 35, http://dx.doi.org/10.1681/asn.2024e59ygyz9

Rizk DV; Kollins D; Papachristofi O; Hach T; Valentin M-A; Merkel T; Renfurm RW; Perkovic V, 2024, 'Effect of Iptacopan on Proteinuria and Complement Biomarkers in IgAN: Interim Analysis of the Phase 3 APPLAUSE-IgAN Study', Journal of the American Society of Nephrology, 35, http://dx.doi.org/10.1681/asn.2024atyr04b6

Pratley RE; Mahaffey KW; Mann JF; Tuttle KR; Rossing P; Idorn T; David J-P; Bosch-Traberg H; Jeppesen OK; Bax WA; Gillard P; Arici M; Shamkhalova M; Perkovic V, 2024, 'Effect of Semaglutide on Mortality Outcomes in the FLOW Trial', Journal of the American Society of Nephrology, 35, http://dx.doi.org/10.1681/asn.20249xpc35vs

Ha JT; Hiremath S; Jun M; Green SC; Wheeler DC; Coyne DW; Perkovic V; Badve SV, 2024, 'Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors in Kidney Disease.', NEJM Evid, 3, pp. EVIDoa2300189, http://dx.doi.org/10.1056/EVIDoa2300189

Neuen BL; Ferguson TW; Jardine M; Neal B; Perkovic V; Bakris GL; Agarwal R; Schloemer P; Farjat AE; Jongs N; Heerspink HJL; Wheeler DC; Chertow GM; Tangri N, 2024, 'Prognostic Enrichment Using the Klinrisk Model: Insights from Landmark Kidney Disease Clinical Trials', Journal of the American Society of Nephrology, 35, pp. 10.1681/asn.2024c0crz6n5, http://dx.doi.org/10.1681/asn.2024c0crz6n5

Yeung EK; Ferguson TW; Tangri N; Vaduganathan M; Arnott CG; Jun M; Kotwal SS; Jardine M; Perkovic V; Heerspink HJL; Neuen BL, 2024, 'Risk-Based Implementation of SGLT2 Inhibitors: Insights from the CANVAS Program and CREDENCE Trial', Journal of the American Society of Nephrology, 35, http://dx.doi.org/10.1681/asn.2024k6fn2ax5

Rizk DV; Kollins D; Papachristofi O; Hach T; Jacinto-Sanders S; Merkel T; Schmouder RL; Kulmatycki KM; Renfurm RW; Perkovic V, 2024, 'Safety and Efficacy of Iptacopan in Patients with IgA Nephropathy with Baseline eGFR 20 to <30 mL/min: Phase 3 APPLAUSE-IgAN Subcohort Results', Journal of the American Society of Nephrology, 35, http://dx.doi.org/10.1681/asn.20241h4rz9f5

Tuttle KR; Mann JF; Sokareva E; Rayner B; Pugliese G; Pratley RE; Perkovic V; Mahaffey KW; Kashihara N; Jeppesen OK; Gumprecht J; Correa-Rotter R; Cherney D; Bosch-Traberg H; Arici M; Rossing P, 2024, 'Semaglutide Reduced Risks of Major Kidney Outcomes Irrespective of CKD Severity in the FLOW Trial', Journal of the American Society of Nephrology, 35, http://dx.doi.org/10.1681/asn.2024bjyvcgfe

Perkovic A; Webster E; Ridker P; Tuttle K; Perkovic V; Neuen B, 2024, 'The Effects of Anti-Inflammatory Agents on Cardiovascular Outcomes: A Systematic Review and Meta-Analysis of Randomised Controlled Clinical Trials', Heart, Lung and Circulation, 33, pp. S539 - S539, http://dx.doi.org/10.1016/j.hlc.2024.06.904

Wong MG; Lv J; Neuen B; Monaghan H; Billot L; Perkovic V; Zhang H; Kim D, 2024, 'WCN24-1001 EFFECT OF CORTICOSTEROIDS ON KIDNEY AND SAFETY OUTCOMES IN IGA NEPHROPATHY ACROSS DIFFERENT LEVELS OF PROTEINURIA AND EGFR: A POST HOC ANALYSIS OF THE TESTING STUDY', Kidney International Reports, 9, pp. S151 - S151, http://dx.doi.org/10.1016/j.ekir.2024.02.310

Perkovic V; Kollins D; Renfurm R; Papachristofi O; Jacinto-Sanders S; Merkel T; Hach T; Rizk DV, 2024, 'WCN24-1506 EFFICACY AND SAFETY OF IPTACOPAN IN PATIENTS WITH IgA NEPHROPATHY: INTERIM RESULTS FROM THE PHASE 3 APPLAUSE-IgAN STUDY', Kidney International Reports, 9, pp. S506 - S506, http://dx.doi.org/10.1016/j.ekir.2024.02.1414

Trimarchi H; Barratt J; Radhakrishnan J; Rizk DV; Sorensen B; Leiske J; Khawaja Z; Campbell K; Perkovic V, 2024, 'WCN24-1837 BEYOND: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED TRIAL OF ZIGAKIBART IN ADULTS WITH IGA NEPHROPATHY', Kidney International Reports, 9, pp. S177 - S177, http://dx.doi.org/10.1016/j.ekir.2024.02.362

Barratt J; Rovin B; Murphy E; Komers R; Trimarchi H; Perkovic V, 2024, 'WCN24-847 SPARSENTAN VS IRBESARTAN IN PATIENTS WITH IMMUNOGLOBULIN A NEPHROPATHY (IgAN): SUBGROUP ANALYSES OF 2-YEAR RESULTS FROM THE PIVOTAL PHASE 3 PROTECT TRIAL', Kidney International Reports, 9, pp. S505 - S506, http://dx.doi.org/10.1016/j.ekir.2024.02.1413

Rheault MN; Alpers CE; Barratt J; Bieler S; Canetta P; Chae DW; Coppock G; Diva U; Gesualdo L; Heerspink HJL; Inrig JK; Kirsztajn GM; Kohan D; Komers R; Kooienga LA; Lieberman K; Mercer A; Noronha IL; Perkovic V; Radhakrishnan J; Rote W; Rovin B; Tesar V; Trimarchi H; Tumlin J; Wong MG; Trachtman H, 2023, 'Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis.', New England Journal of Medicine, 389, pp. 2436 - 2445, http://dx.doi.org/10.1056/NEJMoa2308550

Heerspink HJL; Jongs N; Schloemer P; Little DJ; Brinker M; Tasto C; Karpefors M; Wheeler DC; Bakris G; Perkovic V; Nkulikiyinka R; Rossert J; Gasparyan SB, 2023, 'Development and Validation of a New Hierarchical Composite End Point for Clinical Trials of Kidney Disease Progression', Journal of the American Society of Nephrology, 34, pp. 2025 - 2038, http://dx.doi.org/10.1681/ASN.0000000000000243

Fletcher RA; Jongs N; Chertow GM; McMurray JJV; Arnott C; Jardine MJ; Mahaffey KW; Perkovic V; Rockenschaub P; Rossing P; Correa-Rotter R; Toto RD; Vaduganathan M; Wheeler DC; Heerspink HJL; Neuen BL, 2023, 'Effect of SGLT2 Inhibitors on Discontinuation of Renin–angiotensin System Blockade: A Joint Analysis of the CREDENCE and DAPA-CKD Trials', Journal of the American Society of Nephrology, 34, pp. 1965 - 1975, http://dx.doi.org/10.1681/ASN.0000000000000248

Yu J; Sweeting AN; Gianacas C; Houston L; Lee V; Fletcher RA; Perkovic V; Li Q; Neuen BL; Berwanger O; Heerspink HJL; de Zeeuw D; Arnott C, 2023, 'The effects of canagliflozin in type 2 diabetes in subgroups defined by population-specific body mass index: Insights from the CANVAS Program and CREDENCE trial', Diabetes Obesity and Metabolism, 25, pp. 3724 - 3735, http://dx.doi.org/10.1111/dom.15267

Marx N; Deanfield JE; Gerward S; Hovingh GK; Plunde O; Pratley RE; Staerk-Ostergaard J; Perkovic V, 2023, 'Prevalence of systemic inflammation in individuals with atherosclerotic cardiovascular disease: baseline characteristics from the SELECT, SOUL and FLOW phase 3 trials of semaglutide', European Heart Journal, 44, http://dx.doi.org/10.1093/eurheartj/ehad655.2751

Neuen BL; Perkovic V; Bakris GL; Heerspink HL; Vaduganathan M, 2023, 'Estimated Lifetime Benefits of Combination Therapy With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Non-Steroidal MRAs in Patients With Type 2 Diabetes and Albuminuria', CIRCULATION, 148, http://dx.doi.org/10.1161/circ.148.suppl_1.17437

Heerspink HJL; Vart P; Jongs N; Neuen BL; Bakris G; Claggett B; Vaduganathan M; McCausland F; Docherty KF; Jhund PS; Solomon SD; Perkovic V; McMurray JJV, 2023, 'Estimated lifetime benefit of novel pharmacological therapies in patients with type 2 diabetes and chronic kidney disease: A joint analysis of randomized controlled clinical trials', Diabetes Obesity and Metabolism, 25, pp. 3327 - 3336, http://dx.doi.org/10.1111/dom.15232

Rossing P; Baeres FMM; Bakris G; Bosch-Traberg H; Gislum M; Gough SCL; Idorn T; Lawson J; Mahaffey KW; Mann JFE; Mersebach H; Perkovic V; Tuttle K; Pratley R, 2023, 'The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease', Nephrology Dialysis Transplantation, 38, pp. 2041 - 2051, http://dx.doi.org/10.1093/ndt/gfad009

Back to profile page